Immodulon Therapeutics Limited

📍 London, United Kingdom👥 9 employees💰 Last funded Jan 2016
Biotechnology🌐 immodulon.com
Website LinkedIn
IMMODULON, LEADERS IN IMMUNO-ONCOLOGY Immodulon Therapeutics Ltd. is a privately-owned clinical-stage immuno-oncology company primarily focused on the development of safe, effective and novel treatments for cancer. Its lead drug candidate, IMM-101, has shown promise in early clinical trials, demonstrating potential for the platform. IMM-101 has a unique mechanism of action that should not only make this innovative product applicable to a large range of cancers but, in combination with immune checkpoint inhibitors and other standard-of-care treatments, is expected to enhance their efficacy without increasing the safety burden for the patient.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Immodulon Therapeutics Limited?
Immodulon Therapeutics Limited has 1 investors on record on gritt.io.
When did Immodulon Therapeutics Limited last raise funding?
The most recent investment in Immodulon Therapeutics Limited recorded on gritt.io was in January 2016.
What industry is Immodulon Therapeutics Limited in?
Immodulon Therapeutics Limited operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Immodulon Therapeutics Limited based?
Immodulon Therapeutics Limited is headquartered in London, United Kingdom.